At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 53 enrolled
Drug / intervention
APL-2drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Multicenter, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
In Brief
A Phase 3 clinical trial evaluating APL-2 for Paroxysmal Nocturnal Hemoglobinuria. Completed, enrolled 53 participants across 30 sites in 10 countries.
Detailed Summary
Evaluation of the Efficacy and Safety of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria .
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParoxysmal Nocturnal Hemoglobinuria
CountriesColombia, Hong Kong, Malaysia, Mexico, Peru, Philippines, Poland, Serbia, Singapore, Thailand
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
Enrollment StartAug 2019
First PostedSep 2019
Primary CompletionJun 2021
TodayJul 2026
First PostedSep 11, 2019
Enrollment StartAug 27, 2019
Primary CompletionJun 23, 2021
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 6.8 years ago
Interventions
APL-2drug
Complement (C3) Inhibitor